Invention Grant
- Patent Title: Antibodies specific for epidermal growth factor receptor variant III and their uses
-
Application No.: US16163243Application Date: 2018-10-17
-
Publication No.: US11279764B2Publication Date: 2022-03-22
- Inventor: Oi Kwan Wong , Joyce Ching Chou , Barbra Johnson Sasu
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K39/395 ; C07H21/04 ; C07K16/28 ; C07K16/30 ; A61K39/00

Abstract:
The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.
Public/Granted literature
- US20190194335A1 ANTIBODIES SPECIFIC FOR EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND THEIR USES Public/Granted day:2019-06-27
Information query